Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of uncontrolled epilepsy with primary generalized tonic-clonic (PGTC) seizures and idiopathic generalized epilepsy. Diagnosis should have been established by an electroencephalogram (EEG) with generalized spike-wave discharges within 5 years of the screening visit~* Subject has ≥1 PGTC seizure within the 12 weeks prior to the screening visit~* Subject has a stable dose regimen of 1 to 3 marketed antiepileptic drug(s) (AEDs) with or without additional concurrent stable Vagus Nerve Stimulation (VNS). The VNS must have been in place for at least 6 months prior to study entry with constant settings for at least 28 days prior to the screening visit and during the Baseline Phase. Benzodiazepines will be counted as an AED~Exclusion Criteria:~* Subject has a history of partial-onset seizures or EEG findings consistent with partial onset seizures~* Subject has a history of status epilepticus within the 5-year Period prior to Visit 1~* Subject has a current or previous diagnosis of pseudoseizures, conversion disorders, or other non-epileptic ictal events~* Subject has any medical or psychiatric condition~* Subject has any history of alcohol or drug abuse~* Subject is currently taking felbamate~* Subject has ever taken vigabatrin and has no visual fields examination report available or if results of the examination are abnormal~* Subject is on a ketogenic diet~* Subject has a known sodium channelopathy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).